玻璃体切除术后眼内注射地塞米松植入剂治疗糖尿病性黄斑水肿的临床特征
回顾性观察研究比较玻璃体切除眼与非玻璃体切除眼接受地塞米松植入剂(IVD)治疗糖尿病性黄斑水肿的临床结局,发现两组在中央子场厚度、最佳矫正视力和高眼压发生率上无显著差异,但玻璃体切除眼首次IVD作用持续时间显著更短且12个月内需要更多次治疗。
要点
- 玻璃体切除眼首次IVD作用持续时间显著短于非玻璃体切除眼,且12个月内需要更多次IVD治疗。
- 两组在中央子场厚度、最佳矫正视力和高眼压发生率上无显著组间差异。
- 非玻璃体切除组首次IVD后眼压平均值在2个月达峰,玻璃体切除组在1个月达峰。
核心结论
- IVD的药代动力学和药效动力学在玻璃体切除眼与非玻璃体切除眼之间存在差异。
- 鉴于治疗相对持久有效且临床结果良好,连续IVD治疗可能对既往接受玻璃体切除术的糖尿病性黄斑水肿患者有益。
研究设计与样本
- 回顾性观察研究,比较非玻璃体切除眼与玻璃体切除眼首次IVD治疗后的IVD作用持续时间、眼压趋势和高眼压患病率。
- 记录IVD植入后至12个月的中央子场厚度、最佳矫正视力和眼压。
- 比较两组12个月后的中央子场厚度、最佳矫正视力、IVD治疗次数和高眼压患病率。
主要发现
- 治疗期间两组间中央子场厚度、最佳矫正视力或高眼压患病率无显著差异。
- 玻璃体切除眼首次IVD治疗的作用持续时间显著更短,且在12个月随访期内需要更多次IVD治疗。
- 非玻璃体切除组首次IVD治疗后平均眼压最大值出现在2个月,玻璃体切除组出现在1个月。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To identify the clinical outcomes of intravitreal dexamethasone implantation (IVD) in previously vitrectomized eyes of patients with diabetic macular edema. METHOD: We performed a retrospective observational study. We recorded central subfield thickness, best-corrected visual acuity, and intraocular pressure up to 12 months after IVD implant placement. We compared the duration of IVD action, intraocular pressure trends, and the prevalence of ocular hypertension after the first IVD treatment of nonvitrectomized and vitrectomized eyes. We also compared the central subfield thickness, best-corrected visual acuity, number of IVD treatments, and prevalence of ocular hypertension between the 2 groups after 12 months. RESULTS: We found no significant between-group differences in the central subfield thickness, best-corrected visual acuity, or the prevalence of ocular hypertension during treatment. However, the duration of action of the first IVD treatment was significantly shorter in vitrectomized eyes, and these eyes required more IVD treatments during the 12-month follow-up period. The maximal average intraocular pressure was observed at 2 months after the first IVD treatment in the nonvitrectomized group, but 1 month after the first IVD treatment in the vitrectomized group. CONCLUSION: These findings suggest that the IVD pharmacokinetics and pharmacodynamics differ between vitrectomized and nonvitrectomized eyes. Nevertheless, given the relatively long-lasting effectiveness of the treatment and the good clinical results, consecutive IVD treatments may be beneficial for patients with diabetic macular edema with previously vitrectomized eyes.
引用
- Kwon JW, Park YG. CLINICAL FEATURES OF INTRAVITREAL DEXAMETHASONE IMPLANTATION IN VITRECTOMIZED EYES OF PATIENTS WITH DIABETIC MACULAR EDEMA. Retina. 2022. PMID: 34907121. doi:10.1097/IAE.0000000000003380
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。